ArticlePloS one2020
Controlling the development of the dengue vector Aedes aegypti using HR3 RNAi transgenic Chlamydomonas.
Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 37 citations in OpenAlex.
- Control of Aedes albopictus populations by silencing of the vesicular GABA transporter (vgat) and the vesicular monoamine transporter (vmat) genes using recombinant Chlorella shRNA.Parasites & vectors · 2025Article
- RNA interference knockdown of the nuclear receptor HR3 suppresses vitellogenesis in Chilo suppressalis.Molecular biology reports · 2025Article
- Outlook on RNAi-Based Strategies for ControllingPathogens (Basel, Switzerland) · 2023Review
- Mosquito gene targeted RNAi studies for vector control.Functional & integrative genomics · 2023Review
- Effect of marker-free transgenic Chlamydomonas on the control of Aedes mosquito population and on plankton.Parasites & vectors · 2023Article
- RNAi turns 25:contributions and challenges in insect science.Frontiers in insect science · 2023Review
- Control of Aedes mosquito populations using recombinant microalgae expressing short hairpin RNAs and their effect on plankton.PLoS neglected tropical diseases · 2023Article
- Review
- Development of an RNAi-based microalgal larvicide for the control of Aedes aegypti.Parasites & vectors · 2021Article
- 20-Hydroxyecdysone (20E) signaling as a promising target for the chemical control of malaria vectors.Parasites & vectors · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Aedes aegypti mosquito plays an important role in the spread of diseases, including epidemic ones, such as dengue fever, Zika virus disease, yellow fever, and chikungunya disease. To control the population of Ae.aegypti, we transferred an HR3 RNAi fragment into the microalgae Chlamydomonas, which serves as food for Ae.aegypti larvae. Results showed that the HR3 RNAi transgenic algal strains were lethal to Ae.aegypti. The integumentary system of larvae fed with HR3 RNAi transgenic algal strains was severely damaged. Muscles of the larvae were unevenly distributed and disordered, and their midgut showed disintegration of the intestinal cavity. RNA-Seq results demonstrated that on the 4th day of inoculation with the transgenic algae, the abundance of early expressed genes in the 20E signal transduction pathway of larvae fed with the HR3 RNAi transgenic algal strain significantly reduced. These genes include E74, E75, E93, and 20E receptor complex EcR/USP and FTZ-F1 gene regulated by HR3. In later experiments, a scale test of 300 Ae.aegypti eggs per group was carried out for 30 days, and the survival rate of Ae.aegypti fed with the HR3 RNAi transgenic strain was only 1.3%. These results indicate that the HR3 RNAi transgenic strain exerts obvious insecticidal effect.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.